# XRTX catalysts: XORTX Therapeutics Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/xrtx/catalysts

> XORTX Therapeutics Inc. (XRTX) has no upcoming catalysts in this calendar. The latest recorded is the OXY-101 topline data readout, January 19, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for XRTX?

XORTX Therapeutics Inc. (XRTX) has no upcoming catalysts in this calendar. The latest recorded is the OXY-101 topline data readout, January 19, 2023. Press release filed with the SEC (EX-99): "On January 19, 2023, the Company announced positive topline results from the XRX-OXY-101 - Bridging Pharmacokinetics Clinical Trial (the "Study") characterizing the pharmacokinetics of the" [Calendar and source filings](https://sec-api.dev/companies/xrtx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001171843-25-001931, https://www.sec.gov/Archives/edgar/data/1729214/000117184325001931/exh_991.htm (retrieved 2026-11-12). Last confirmed 2026-03-20. Cite: https://sec-api.dev/companies/xrtx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | XORTX Therapeutics Inc. |
| Ticker | XRTX (Nasdaq) |
| SEC CIK | 1729214 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/xrtx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 13, 2022 | [OXY-101 topline data readout](https://sec-api.dev/pdufa/oxy-101) | XRTX |  | completed, positive | "On July 13, 2022, the Company announced positive topline results from Part 1 of the three-part (now four part) XRX-OXY-101 PK Clinical Trial showing a substantial increase in oral bioavailability of two versions of XORTX's proprietary oxypurinol formulation compared to a control formulation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1729214/000117184325001931/exh_991.htm)) |
| August 22, 2022 | [OXY-101 topline data readout](https://sec-api.dev/pdufa/oxy-101) | XRTX |  | completed, positive | "On August 22, 2022, the Company announced positive topline results from its XRX-OXY-101 PK Clinical Trial - Part 2 showing a substantial increase in oral bioavailability of XORLOTM provided with food compared to the fasted state." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1729214/000117184325001931/exh_991.htm)) |
| January 19, 2023 | [OXY-101 topline data readout](https://sec-api.dev/pdufa/oxy-101) | XRTX |  | completed, positive | "On January 19, 2023, the Company announced positive topline results from the XRX-OXY-101 - Bridging Pharmacokinetics Clinical Trial (the "Study") characterizing the pharmacokinetics of the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1729214/000117184325001931/exh_991.htm)) |

## Drugs

- [OXY-101](https://sec-api.dev/pdufa/oxy-101): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/xrtx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "XRTX catalysts: XORTX Therapeutics Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/xrtx/catalysts

```bibtex
@misc{secapidev_companies_xrtx_catalysts_20261116,
  title        = {XRTX catalysts: XORTX Therapeutics Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/xrtx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_xrtx_catalysts_20261116","title":"XRTX catalysts: XORTX Therapeutics Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/xrtx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
